230 related articles for article (PubMed ID: 25356783)
1. Statistical evaluation of several methods for cut-point determination of immunogenicity screening assay.
Shen M; Dong X; Tsong Y
J Biopharm Stat; 2015; 25(2):269-79. PubMed ID: 25356783
[TBL] [Abstract][Full Text] [Related]
2. Non-normal random effects models for immunogenicity assay cut point determination.
Zhang J; Yu B; Zhang L; Roskos L; Richman L; Yang H
J Biopharm Stat; 2015; 25(2):295-306. PubMed ID: 25356500
[TBL] [Abstract][Full Text] [Related]
3. Statistical considerations in setting product specifications.
Dong X; Tsong Y; Shen M
J Biopharm Stat; 2015; 25(2):280-94. PubMed ID: 25358110
[TBL] [Abstract][Full Text] [Related]
4. Using tolerance intervals for assessment of pharmaceutical quality.
Dong X; Tsong Y; Shen M; Zhong J
J Biopharm Stat; 2015; 25(2):317-27. PubMed ID: 25356617
[TBL] [Abstract][Full Text] [Related]
5. Testing assay linearity over a pre-specified range.
Yang H; Novick SJ; LeBlond D
J Biopharm Stat; 2015; 25(2):339-50. PubMed ID: 25356663
[TBL] [Abstract][Full Text] [Related]
6. Quality assurance test of delivered dose uniformity of multiple-dose inhaler and dry powder inhaler drug products.
Tsong Y; Dong X; Shen M; Lostritto RT
J Biopharm Stat; 2015; 25(2):328-38. PubMed ID: 25357132
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity assay cut point determination using nonparametric tolerance limit.
Zhang J; Li W; Roskos LK; Yang H
J Immunol Methods; 2017 Mar; 442():29-34. PubMed ID: 28063769
[TBL] [Abstract][Full Text] [Related]
8. Guest editors' note: special issue on recent developments in statistical approaches for chemistry and manufacturing control (CMC) and quality-by-design(QbD).
Tsong Y; Yang H
J Biopharm Stat; 2015; 25(2):233. PubMed ID: 25437635
[No Abstract] [Full Text] [Related]
9. One- and two-stage Arrhenius models for pharmaceutical shelf life prediction.
Fan Z; Zhang L
J Biopharm Stat; 2015; 25(2):307-16. PubMed ID: 25358076
[TBL] [Abstract][Full Text] [Related]
10. A novel gamma-fitting statistical method for anti-drug antibody assays to establish assay cut points for data with non-normal distribution.
Schlain B; Amaravadi L; Donley J; Wickramasekera A; Bennett D; Subramanyam M
J Immunol Methods; 2010 Jan; 352(1-2):161-8. PubMed ID: 19891969
[TBL] [Abstract][Full Text] [Related]
11. Statistical considerations for calculation of immunogenicity screening assay cut points.
Hoffman D; Berger M
J Immunol Methods; 2011 Oct; 373(1-2):200-8. PubMed ID: 21906599
[TBL] [Abstract][Full Text] [Related]
12. Dissolution curve comparisons through the F(2) parameter, a Bayesian extension of the f(2) statistic.
Novick S; Shen Y; Yang H; Peterson J; LeBlond D; Altan S
J Biopharm Stat; 2015; 25(2):351-71. PubMed ID: 25357203
[TBL] [Abstract][Full Text] [Related]
13. A statistical approach to determining criticality of residual host cell DNA.
Yang H; Wei Z; Schenerman M
J Biopharm Stat; 2015; 25(2):234-46. PubMed ID: 25358029
[TBL] [Abstract][Full Text] [Related]
14. Analytical procedure validation and the quality by design paradigm.
Rozet E; Lebrun P; Michiels JF; Sondag P; Scherder T; Boulanger B
J Biopharm Stat; 2015; 25(2):260-8. PubMed ID: 25357001
[TBL] [Abstract][Full Text] [Related]
15. Methods and applications of percentile estimation.
Xia Q; Tsong Y; Weng YT
J Biopharm Stat; 2020 Mar; 30(2):267-276. PubMed ID: 31237475
[TBL] [Abstract][Full Text] [Related]
16. A quality by design approach for longitudinal quality attributes.
Lebrun P; Giacoletti K; Scherder T; Rozet E; Boulanger B
J Biopharm Stat; 2015; 25(2):247-59. PubMed ID: 25360720
[TBL] [Abstract][Full Text] [Related]
17. A new method for identification of outliers in immunogenicity assay cut point data.
Zhang J; Arends RH; Kubiak RJ; Roskos LK; Liang M; Lee N; Chen CC; Yang H
J Immunol Methods; 2020; 484-485():112817. PubMed ID: 32615125
[TBL] [Abstract][Full Text] [Related]
18. Sample size consideration for immunoassay screening cut-point determination.
Zhang J; Zhang L; Yang H
J Biopharm Stat; 2014; 24(3):535-45. PubMed ID: 24697778
[TBL] [Abstract][Full Text] [Related]
19. Role of the standard deviation in the estimation of benchmark doses with continuous data.
Gaylor DW; Slikker W
Risk Anal; 2004 Dec; 24(6):1683-7. PubMed ID: 15660621
[TBL] [Abstract][Full Text] [Related]
20. Statistical methods and tool for cut point analysis in immunogenicity assays.
Zhang L; Zhang JJ; Kubiak RJ; Yang H
J Immunol Methods; 2013 Mar; 389(1-2):79-87. PubMed ID: 23305975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
